Ileal neobladder for urinary bladder replacement following total pelvic exenteration for rectal carcinoma.
OBJECTIVE
The aim of this study was to determine the feasibility of using the ileal neobladder as a substitute for the urinary bladder following total pelvic exenteration for rectal carcinoma.


METHODS
Between 1992 and 1998, we performed total pelvic exenteration with ileal neobladder in 5 men with rectal carcinoma. Four patients had primary tumors, and one had recurrent disease after low anterior resection for rectal carcinoma. Histological types were adenocarcinoma in 4 and squamous cell carcinoma in 1. Invaded organs were: the urinary bladder in 1, the urinary bladder and prostate in 2, the prostate and seminal vesicle in 1, and the prostate in 1.


RESULTS
There was no operative death. In 1 patient, an ileal conduit was needed because of partial necrosis of the neobladder. Minor leakage on the dorsal wall of the neobladder occurred in 2 patients, which was successfully stopped with simple closure and a gluteus maximus fasciocutaneous flap, respectively. All except one patient with the ileal conduit could void via the urethra. Complete daytime urinary continence was achieved, but nocturnal continence was maintained with voiding once or twice per night. As the urodynamic state, the mean maximum flow rate was 20.9 ml/s (range 9.0-34.1), the mean average flow rate was 7.7 ml/s (range 3.0-11.0), and the mean voided volume was 285.5 ml (range 160-432). The mean length of follow-up was 47.8 months. One patient died of local recurrence 38 months postoperatively, and 1 died of pneumonia 10 months postoperatively. Both patients could void via the urethra until death. The other three patients are currently alive without any evidence of recurrence.


CONCLUSIONS
Although total pelvic exenteration is a laborious surgical procedure, an ileal neobladder could be a good alternative to the urinary bladder enabling the patients to void via the urethra with urinary continence.
Department of Surgery, Shinko Hospital, Kobe, Japan. CE36937@notice.kobelco.jp
S
S
Yamamoto
N
N
Yamanaka
T
T
Maeda
Y
Y
Uchida
S
S
Yabe
M
M
Nakano
S
S
Sakano
Y
Y
Yamada
A
A
Takenaka
M
M
Yamamoto
D000230:Adenocarcinoma / Q000556:secondary* / Q000601:surgery; D000368:Aged; D002294:Carcinoma, Squamous Cell / Q000556:secondary* / Q000601:surgery; D005500:Follow-Up Studies; D006801:Humans; D007082:Ileum; D008297:Male; D008875:Middle Aged; D010385:Pelvic Exenteration / Q000379:methods*; D012004:Rectal Neoplasms / Q000473:pathology* / Q000601:surgery; D016896:Treatment Outcome; D001749:Urinary Bladder Neoplasms / Q000556:secondary* / Q000601:surgery*; D014547:Urinary Diversion / Q000379:methods*; D013521:Urologic Surgical Procedures, Male / Q000379:methods